Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Daniel Patrick O'Day

At a glance: Daniel Patrick O'Day is CEO, Chair at Gilead Sciences (GILD). Their latest SEC Form 4, filed Nov 6, 2026, reported a sale of $18.0M. On file: 0 purchase lines ($0) and 36 sale lines ($77.5M).

Disclosed holdings: about $92.2M of GILD stock: 551,683 shares reported on their latest Form 4 (filed Nov 6, 2026), valued at the Nov 19, 2026 close of $167.13. This counts only GILD shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

CEO, Chair at Gilead Sciences, Inc. (GILD)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $77.5M

Daniel Patrick O'Day's InsiderPrint

36 trades from SEC Form 4 filings, 2025 to 2026, drawn as one fingerprint.

InsiderPrint of Daniel Patrick O'Day: 36 trades, 2025 to 20262025: 0 buys, 5 sales2026: 0 buys, 31 sales

Reading this print: Almost only sells, trading about 35 times a year, typically $861K a trade; most sales are on a pre-planned 10b5-1 schedule.

  • Bump outward: a purchase (0)
  • Dent inward: a sale (36)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Insiders with a similar print

  1. Mark D. PapermasterCTO · AMD · 100% match
  2. Sheldon Richard BentleyFounder · CSAI · 100% match
  3. Alclear Investments, LLCSee Remarks · YOU · 100% match
  4. Benjamin SilbermannDirector · PINS · 100% match
  5. Steven M. QuirkChief Brokerage Officer · HOOD · 100% match

Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.

Reported trades

Filed Stock Type Shares Price Value Since
Nov 6SEC GILDGilead Sciences, Inc. Sell Plan 102,619551,683 held (−16%) $175.16 $18.0M -4.6%
Nov 6SEC GILDGilead Sciences, Inc. Sell Plan 9,810551,683 held (−2%) $175.17 $1.7M -4.6%
Nov 2SEC GILDGilead Sciences, Inc. Sell Plan 15,881566,683 held (−3%) $175.25 $2.8M -4.6%
Nov 2SEC GILDGilead Sciences, Inc. Sell Plan 1,600565,083 held (−0%) $167.40 $268K -0.2%
Nov 2SEC GILDGilead Sciences, Inc. Sell Plan 1,700563,383 held (−0%) $168.10 $286K -0.6%
Nov 2SEC GILDGilead Sciences, Inc. Sell Plan 1,904561,479 held (−0%) $169.27 $322K -1.3%
Nov 2SEC GILDGilead Sciences, Inc. Sell Plan 7,796553,683 held (−1%) $170.35 $1.3M -1.9%
Nov 2SEC GILDGilead Sciences, Inc. Sell Plan 2,000551,683 held (−0%) $171.06 $342K -2.3%
Oct 2SEC GILDGilead Sciences, Inc. Sell Plan 12,000569,683 held (−2%) $147.72 $1.8M +13.1%
Oct 2SEC GILDGilead Sciences, Inc. Sell Plan 3,000566,683 held (−1%) $148.63 $446K +12.5%
Sep 2SEC GILDGilead Sciences, Inc. Sell Plan 1,600590,533 held (−0%) $147.51 $236K +13.3%
Sep 2SEC GILDGilead Sciences, Inc. Sell Plan 7,992582,541 held (−1%) $148.36 $1.2M +12.7%
Sep 2SEC GILDGilead Sciences, Inc. Sell Plan 5,408577,133 held (−1%) $149.38 $808K +11.9%
Aug 4SEC GILDGilead Sciences, Inc. Sell Plan 6,700600,433 held (−1%) $129.66 $869K +28.9%
Aug 4SEC GILDGilead Sciences, Inc. Sell Plan 7,700592,733 held (−1%) $130.80 $1.0M +27.8%
Aug 4SEC GILDGilead Sciences, Inc. Sell Plan 600592,133 held (−0%) $131.34 $79K +27.3%
Jul 2SEC GILDGilead Sciences, Inc. Sell Plan 11,900610,233 held (−2%) $126.09 $1.5M +32.6%
Jul 2SEC GILDGilead Sciences, Inc. Sell Plan 3,100607,133 held (−1%) $127.08 $394K +31.5%
Jun 2SEC GILDGilead Sciences, Inc. Sell Plan 10,900621,667 held (−2%) $131.10 $1.4M +27.5%
Jun 2SEC GILDGilead Sciences, Inc. Sell Plan 3,062618,605 held (−0%) $132.22 $405K +26.4%
Jun 2SEC GILDGilead Sciences, Inc. Sell Plan 1,038617,567 held (−0%) $132.97 $138K +25.7%
Apr 29SEC GILDGilead Sciences, Inc. Sell Plan 6,950635,617 held (−1%) $128.79 $895K +29.8%
Apr 29SEC GILDGilead Sciences, Inc. Sell Plan 3,050632,567 held (−0%) $130.01 $397K +28.6%
Mar 30SEC GILDGilead Sciences, Inc. Sell Plan 10,000642,567 held (−2%) $136.82 $1.4M +22.2%
Mar 2SEC GILDGilead Sciences, Inc. Sell Plan 3,481648,827 held (−1%) $144.04 $501K +16.0%
Mar 2SEC GILDGilead Sciences, Inc. Sell Plan 6,419642,408 held (−1%) $145.18 $932K +15.1%
Mar 2SEC GILDGilead Sciences, Inc. Sell Plan 100642,308 held (−0%) $145.71 $15K +14.7%
Feb 6SEC GILDGilead Sciences, Inc. Sell Plan 115,640613,912 held (−16%) $150.00 $17.3M +11.4%
Jan 29SEC GILDGilead Sciences, Inc. Sell Plan 5,032561,666 held (−1%) $139.54 $702K +19.8%
Jan 29SEC GILDGilead Sciences, Inc. Sell Plan 4,968556,698 held (−1%) $140.24 $697K +19.2%
Jan 26SEC GILDGilead Sciences, Inc. Sell Plan 115,640566,698 held (−17%) $135.00 $15.6M +23.8%
Dec 30SEC GILDGilead Sciences, Inc. Sell Plan 10,000566,698 held (−2%) $124.83 $1.2M +33.9%
Dec 1SEC GILDGilead Sciences, Inc. Sell Plan 3,212577,991 held (−1%) $125.91 $404K +32.7%
Dec 1SEC GILDGilead Sciences, Inc. Sell Plan 6,788571,203 held (−1%) $126.84 $861K +31.8%
Oct 29SEC GILDGilead Sciences, Inc. Sell Plan 7,978583,225 held (−1%) $119.54 $954K +39.8%
Oct 29SEC GILDGilead Sciences, Inc. Sell Plan 2,022581,203 held (−0%) $118.82 $240K +40.7%
  • Sell

    CEO, Chair Daniel Patrick O'day sold $18.0M of GILD at $175.16 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CEO, Chair Daniel Patrick O'day sold $1.7M of GILD at $175.17 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CEO, Chair Daniel Patrick O'day sold $2.8M of GILD at $175.25 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CEO, Chair Daniel Patrick O'day sold $268K of GILD at $167.40 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CEO, Chair Daniel Patrick O'day sold $286K of GILD at $168.10 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CEO, Chair Daniel Patrick O'day sold $322K of GILD at $169.27 — pre-scheduled 10b5-1 plan sale.

Follow Daniel Patrick O'Day

Get one email when Daniel Patrick O'Day files a new purchase or sale. Free.

At most one email a day about Daniel Patrick O'Day, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.